The company said, “The Company is reaffirming its full-year 2025 revenue outlook, reflecting confidence in its continued commercial execution and portfolio performance.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CPRX:
- Catalyst Pharmaceuticals reports Q1 EPS 68c, consensus 53c
- Catalyst Pharma Reports Record Q1 2025 Financial Results
- CPRX Earnings this Week: How Will it Perform?
- Catalyst Pharmaceuticals price target raised to $34 from $33 at BofA
- Catalyst Pharmaceuticals announces Health Canada’s acceptance of AGAMREE NDS
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue